OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
November 05, 2020
Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.
November 04, 2020
Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.
August 13, 2020
The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.
June 11, 2020
The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
June 10, 2020
Catalent will use its GPEx cell line development technology to create a cell line expressing the recombinant VLP at its Madison, WI facility.
April 30, 2020
Solentim and ATUM will bundle together the Leap-In Transposase platform with the VIPS single cell cloning instrument for cell line development.
April 16, 2020
This milestone achievement will allow the companies to move forward with developing a GMP-compliant manufacturing process for clinical testing.
January 31, 2020
Abcam has purchased Applied StemCell’s (ASC’s) gene editing platform and oncology product portfolio, adding comprehensive cell editing capabilities and engine to support expansion of existing “off-the-shelf” cell lines.
January 16, 2020
The next-generation gene editing system can be applied to the development of novel cell and gene therapies.
January 15, 2020
ProBioGen and Lava Therapeutics have closed the cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.